Dyslipidemia

Managing dyslipidemia in your ASCVD patients according to the new guidelines

Managing dyslipidemia in your ASCVD patients according to the new guidelines

Act Now for your ACS Patients

Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)

Overview of adherence data with LLT highlighting the most recent data with PCSK9i

Lipid management in patients with ACS/ASCVD

Improving Lipid Management for Patients Post-ACS

Identifying and treating patients with high Lipidaemia risk post-ACS

Atherosclerosis: Identifying risks and improving outcomes

Public health recommendations for Lp(a) measurement

APSC Consensus Recommendations on Dyslipidemia

Should we encourage earlier and broader use of combination therapies in dyslipidemia?

Possible Challenges Post One Year of ESC/EAS Guidelines

Relationship Between LDL-C LLTs and Risk of Stroke

Lp(a) as ASCVD risk factor

Cardiovascular Disease in Saudi Arabia: Facts and the Way Forward

ACC/AHA vs ESC/EAS LDL–C recommendations for residual risk reduction in ASCVD: A simulation study from Da Vinci

Prospective evaluation of lipid management following acute coronary syndrome in Saudi Arabia

Approach for Patients with PAD and T2D: Focus on LDL-C Control

Cardiovascular diseases (CVDs) are the leading cause of death globally¹

According to the World Health Organization, an estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths¹. Of these deaths, 85% were due to myocardial infarction or stroke¹. A CV event is a highly traumatic experience for patients and their families². It takes a heavy emotional toll, brings widespread disability and significantly impedes quality of life^3,4.

Lipid Management in Patients with Diabetes Mellitus

Approach for Patients with CAD: Focus on LDL-C Control

Atherosclerotic Cardiovascular Disease Risk Assessment

Achievement of lipid modification goals with Statins & Ezetimibe

ESC/EAS 2019 international guidelines